Literature DB >> 17052304

Intrapleural heparin or heparin combined with human recombinant DNase is not effective in the treatment of empyema in a rabbit model.

Oner Dikensoy1, Zhiwen Zhu, Moon Jun Na, Huai Liao, Edwin Donnelly, Richard W Light.   

Abstract

OBJECTIVE AND
BACKGROUND: The aim of this study was to investigate the effectiveness of intrapleural heparin or heparin combined with human recombinant DNase in the treatment of empyema.
METHODS: Empyema was induced in rabbits with an intrapleural injection of 10(9)Pasteurella multicoda organisms in infusion agar via a surgically placed chest tube. Once empyema was verified, a blinded investigator administered drugs via the chest tube. There were three treatment groups each with six rabbits. One group was given 1000 IU heparin, a second group was given 1000 IU heparin plus 1 mg of human recombinant DNase via chest tube and the control group received saline. The rabbits received treatment every 12 h for a total of six treatments and the volume of each treatment was 3 mL. The animals were sacrificed at day 10 and the amount of empyema and pleural thickening was scored macroscopically on a scale of 0-6.
RESULTS: The total volume of pleural effusion aspirated was significantly higher in the heparin group (25.8+/-10.7 mL) compared with either saline (8+/-8.9) or heparin plus human recombinant DNase (6.8+/-6.1) groups (P=0.003). The mean empyema and pleural thickening scores did not differ significantly between the groups (P=0.8, P=0.5 respectively). A weak correlation was found between total volume of aspirated pleural fluid and pleural parameters of white blood cell counts and LDH levels (r=0.546 and P=0.02, r=0.631 and P=0.02 respectively).
CONCLUSION: The intrapleural administration of 1000 IU heparin alone or in combination with 1 mg of human recombinant DNase is no more effective than saline in the treatment of empyema in rabbits. Intrapleural heparin significantly increased the drainage of pleural fluid compared with the combination and saline group.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17052304     DOI: 10.1111/j.1440-1843.2006.00934.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  4 in total

Review 1.  Intrapleural tissue plasminogen activator and deoxyribonuclease therapy for pleural infection.

Authors:  Francesco Piccolo; Natalia Popowicz; Donny Wong; Yun Chor Gary Lee
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

2.  Intrapleural administration of DNase alone for pleural empyema.

Authors:  Vladimir Bobek; Andrzej Majewski; Katarina Kolostova; Adam Rzechonek; Robert Lischke; Jan Schutzner; Grzegorz Kacprzak
Journal:  Int J Clin Exp Med       Date:  2015-11-15

3.  Precision targeting of the plasminogen activator inhibitor-1 mechanism increases efficacy of fibrinolytic therapy in empyema.

Authors:  Galina Florova; René A Girard; Ali O Azghani; Krishna Sarva; Ann Buchanan; Sophia Karandashova; Christian J DeVera; Danna Morris; Mignote Chamiso; Kathleen Koenig; Douglas B Cines; Steven Idell; Andrey A Komissarov
Journal:  Physiol Rep       Date:  2021-05

Review 4.  From Bedside to the Bench-A Call for Novel Approaches to Prognostic Evaluation and Treatment of Empyema.

Authors:  Sophia Karandashova; Galina Florova; Steven Idell; Andrey A Komissarov
Journal:  Front Pharmacol       Date:  2022-01-20       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.